This bill reenacts and amends the definitions section of chapter 18.64 RCW, adds new sections to that chapter, and creates a temporary statutory authorization allowing pharmacists to prescribe a specified list of products and categories beginning December 1, 2026. The authorized items include immunizations, opioid antagonists and addiction treatments, epinephrine autoinjectors, antihistamines, tobacco cessation products, HIV prevention medications, tuberculin skin testing products, hormonal contraception, travel-related medications, and certain other drugs or devices for minor, generally self-limiting conditions or team-based care. That new pharmacist prescribing section expires January 1, 2030. The pharmacy quality assurance commission may adopt rules to implement the act. The bill also amends RCW 69.41.030 to identify authorized practitioners whose orders permit sale, delivery, possession, or use of legend drugs, explicitly listing many licensed professionals and including pharmacists to the extent permitted under chapter 18.64 RCW. It revises penalties and procedures under that statute: sale, delivery, or possession with intent to sell or deliver a legend drug is a class B felony; knowing possession and knowing use of a legend drug in a public place are misdemeanors with an express encouragement for prosecutors to divert eligible cases. Law enforcement is encouraged to offer referrals to assessment or services and certain arrest and booking alternatives for specified violations. The bill defines “public place” by cross-reference and defines “use any legend drug” as introducing the drug into the body. The act adds or updates several statutory definitions (for example, “shared pharmacy services,” “secretary,” “statement of deficiency,” and “wholesaler”) and reenacts numerous existing definitions in RCW 18.64.011. Important details are not included in the provided text: the full, amended language of RCW 69.41.030, the complete definition of “prescription” (cut off in the materials), and any requirements or limits (such as required training, certification, supervision, patient screening, or documentation) that pharmacists must meet to exercise the new prescribing authority are not shown.

If enacted, starting December 1, 2026 and lasting until January 1, 2030 pharmacists will be able to directly prescribe a defined list of vaccines, medications and devices (including immunizations, naloxone and addiction treatments, epinephrine autoinjectors, hormonal contraception, PrEP, certain travel and minor-condition medicines, and products tied to CLIA‑waived tests or team-based records). That will likely expand where and how people get these products by shifting some prescribing and dispensing work into pharmacies, and the Pharmacy Quality Assurance Commission will be expected to write rules to make the change work in practice. The people and groups most affected are pharmacists and licensed pharmacies, who will take on new clinical and operational responsibilities and may face costs for training, staffing, or new workflows; patients, who will probably have easier access to these products; the commission and Department of Health, which will need to develop implementing rules; and law enforcement and prosecutors, whose handling of illegal possession or use of legend drugs is clarified with specified penalties and encouraged diversion options. Important details about required training, documentation, limits on pharmacist authority, and how services must be delivered are not included in the extracted text, so the exact scope of duties and compliance costs remains uncertain.